WO2003055890A1 - Composes derives de thienopyrimidine utilises comme inhibiteurs de la prolylpeptidase, inducteurs d'apoptose et agents de traitement anticancereux - Google Patents

Composes derives de thienopyrimidine utilises comme inhibiteurs de la prolylpeptidase, inducteurs d'apoptose et agents de traitement anticancereux Download PDF

Info

Publication number
WO2003055890A1
WO2003055890A1 PCT/US2002/041168 US0241168W WO03055890A1 WO 2003055890 A1 WO2003055890 A1 WO 2003055890A1 US 0241168 W US0241168 W US 0241168W WO 03055890 A1 WO03055890 A1 WO 03055890A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
optionally substituted
halogen
ring
heterocyclic ring
Prior art date
Application number
PCT/US2002/041168
Other languages
English (en)
Inventor
Jacques Dumas
Robert Sibley
Jill Wood
Original Assignee
Bayer Pharmaceuticals Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corporation filed Critical Bayer Pharmaceuticals Corporation
Priority to AU2002364211A priority Critical patent/AU2002364211A1/en
Publication of WO2003055890A1 publication Critical patent/WO2003055890A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Definitions

  • the present invention relates to:
  • compositions comprising one or more of the compounds or purified stereoisomers or stereoisomer mixtures of the invention, or their salts or prodrugs forms thereof, with a pharmaceutically acceptable ingredient;
  • X is OR 3 or NR 3 IU; Ri is selected from the group consisting of hydrogen and -( -C5) alkyl;
  • R is selected from the group consisting of
  • R 3 is selected from the group consisting of hydrogen and -(C ⁇ -C 5 ) alkyl
  • R 4 is selected from the group consisting of: (a) -(CH 2 ) m -A, where A is:
  • (a2) a saturated or fully unsaturated four to eight membered heterocyclic ring, containing one to four heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, wherein said heterocyclic ring system contains at least one carbon atom and wherein said ring is optionally substituted with up to three substituents selected from the group consisting of amino, cyano, halogen, hydroxy, nitro, oxo, -(C 1 -C 5 ) alkoxy, -(CVC 5 ) alkylamino, and -(C Cs) linear or branched alkyl optionally substituted by halogen, (a3) a fused bicyclo ring wherein one ring is a saturated or fully unsaturated five to six membered heterocyclic ring which contains one to three heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, wherein said heterocyclic ring contains at least one carbon atom, and the other ring is a saturated or fully unsaturated five to eight membered
  • (b4) a saturated or fully unsaturated four to eight membered heterocyclic ring, containing one to four heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, wherein said ring contains at least one carbon atom, (b5) -(C 6 -C 10 )-aryl, wherein (b4) and (b5) are optionally substituted with up to three substituents selected from the group consisting of amino, cyano, halogen, hydroxy, nitro, oxo, -(CrC 5 ) alkoxy-, -(C 1 -C5) alkylamino and -(C 1 -C 5 ) linear or branched alkyl optionally substituted by halogen;
  • R 3 and ⁇ form, together with the nitrogen to which they are attached, a saturated or fully unsaturated four to eight-membered heterocyclic ring, containing zero to four additional heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, and wherein said ring structure contains at least one carbon atom and wherein said ring is optionally substituted by one to two substituents selected from the group consisting of amino, cyano, hydroxy, - (CrC 5 ) alkoxy-, -(C ⁇ -C 5 ) alkylamino and -(C ⁇ -C 5 ) linear or branched alkyl optionally substituted by halogen;
  • R 5 is:
  • R 6 and R 7 are independently selected from the group consisting of
  • the preferred compounds of the invention have general formula (I) and are further defined below.
  • the definitions for the various groups and variables represent the preferred definitions when they differ from those as broadly defined above, and are to be understood as independent of each other.
  • the preferred compounds of the invention have the formula (I) ) q -R 2
  • X is NR 3 R t ;
  • Ri is selected from the group consisting of hydrogen and -(C ⁇ -C 5 ) alkyl
  • R 2 is selected from the group consisting of (a) -(C 6 -C 8 ) cycloalkyl; (b) phenyl; and
  • R 3 is selected from the group consisting of hydrogen and -(C 1 -C 5 ) alkyl
  • i is selected from the group consisting of:
  • A is: (al) -(C 5 -C 8 ) cycloalkyl, optionally substituted with -(C ⁇ -C 5 ) alkoxy, or -(C ⁇ -C 5 ) alkylamino, (a2) a saturated or fully unsaturated five to six membered heterocyclic ring, containing one to two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, wherein said heterocyclic ring system contains at least one carbon atom and wherein said ring is optionally substituted with up to two substituents selected from the group consisting of cyano, halogen, oxo, -(CrC 5 ) alkoxy, -(C ⁇ -C 5 ) alkylamino, and -(C ⁇ -C 5 ) linear or branched alkyl optionally substituted by halogen,
  • (a3) a fused bicyclo ring wherein one ring is a saturated or fully unsaturated five to six membered heterocyclic ring which contains one to two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, wherein said heterocyclic ring contains at least one carbon atom, and the other ring is a saturated or fully unsaturated five to eight membered carbocycle, (a4) phenyl substituted with a saturated or fully unsaturated five to six membered heterocyclic ring, containing one to two heteroatoms selected from the group consisting of nitrogen and oxygen,
  • R 3 and j form, together with the nitrogen to which they are attached, a saturated five to eight-membered heterocyclic ring, containing zero to one additional heteroatom selected from the group consisting of nitrogen, oxygen and sulfur, and wherein said ring structure contains at least one carbon atom and wherein said ring is optionally substituted by one to two substituents selected from the group consisting of -(CrC 5 ) alkoxy-, -(C ⁇ -C 5 ) alkylamino and -(C ⁇ -C 5 ) linear or branched alkyl optionally substituted by halogen;
  • R 6 and R 7 are independently selected from the group consisting of
  • a fused bicyclo ring wherein one ring is a saturated or fully unsaturated five to six membered heterocyclic ring which contains one to two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, wherein said heterocyclic ring contains at least one carbon atom, wherein said heterocyclic ring contains at least one carbon atom and the other ring is a saturated six membered carbocycle, and
  • n and p are independently an integer from 0 - 5; n is an integer from 0 - 3; q is an integer from 0 - 1 ; and q + (m or p) equals an integer from 1 - 6;
  • the more preferred compounds of the invention have general formula (I) and are further defined below.
  • the definitions for the various groups and variables represent the more preferred definitions when they differ from those as broadly defined above, and are to be understood as independent of each other.
  • R 2 is selected from the group consisting of
  • R 3 is hydrogen
  • (a3) a fused bicyclo ring wherein one ring is a saturated or fully unsaturated five to six membered heterocyclic ring which contains one to two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, wherein said heterocyclic ring contains at least one carbon atom, and the other ring is a fully unsaturated six membered carbocycle,
  • R 3 and R 4 form, together with the nitrogen to which they are attached, a saturated five to six-membered heterocyclic ring, containing zero to one additional heteroatom selected from the group consisting of nitrogen, oxygen and sulfur, and wherein said ring structure contains at least one carbon atom and wherein said ring is optionally substituted by one to two substituents selected from the group consisting of -(C 1 -C 5 ) alkoxy, and -(CrCs) linear or branched alkyl optionally substituted by halogen;
  • R 5 is:
  • R 6 and R 7 are independently selected from the group consisting of
  • n and p are independently an integer from 0 - 3; n is an integer from 0 - 1 ; q is an integer from 0 - 1 ; and q + (m or p) equals an integer from 1 - 4;
  • Salts are especially the pharmaceutically acceptable salts of compounds of formulae (I) or (II) such as, for example, organic or inorganic acid addition salts of compounds of formulae
  • Suitable inorganic acids include but are not limited to halogen acids (such as hydrochloric acid), sulfuric acid, or phosphoric acid.
  • Suitable organic acids include but are not limited to carboxylic, phosphonic, sulfonic, or sulfamic acids, with examples including acetic acid, trifluoroacetic acid, propionic acid, octanoic acid, decanoic acid, dodecanoic acid, glycolic acid, lactic acid, 2- or 3-hydroxybutyric acid, ⁇ -aminobutyric acid (GAB A), gluconic acid, glucosemonocarboxylic acid, benzoic acid, salicylic acid, phenylacetic acid, mandelic acid, methanesulfonic acid, trifluoromethanesulfonic acid, fumaric acid, oxalic acid, succinic acid, adipic acid, pimelic acid, suberic acid, azeiaic acid, malic acid, tart
  • pharmaceutically acceptable salts include acid salts of inorganic bases, such as salts containing alkaline cations (e.g., Li + Na + or K + ), alkaline earth cations (e.g., Mg +2 , Ca +2 or Ba +2 ), the ammonium cation, as well as acid salts of organic bases, including aliphatic and aromatic substituted ammonium, and quaternary ammonium cations such as those arising from protonation or peralkylation of triethylamine, NN-diethylamine, NN- dicyclohexylamine, pyridine, NN-dimethylaminopyridine (DMAP), 1,4- diazabicyclo[2.2.2]octane (DABCO), l,5-diazabicyclo[4.3.0]non-5-ene (DBN) and 1,8- diazabicyclo[5.4.0]undec-7-ene (DBU).
  • alkaline cations
  • Prodrugs are considered to be any covalently bonded carriers which release the active parent compound of formula (I) or (II) in vivo. Formation of prodrugs is well known in the art in order to enhance the properties of the parent compound; such properties include solubility, absorption, biostability and release time (see “Pharmaceutical Dosage Form and Drug Delivery Systems” (Sixth Edition), edited by Ansel et al., publ. by Williams & Wilkins, pgs. 27-29, (1995) which is hereby incorporated by reference).
  • prodrugs of the disclosed compounds of formula (I) and (II) are designed to take advantage of the major drug biotransformation reactions and are also to be considered within the scope of the invention.
  • Major drug biotransformation reactions include N- dealkylation, O-dealkylation, aliphatic hydroxylation, aromatic hydroxylation, N-oxidation, S-oxidation, deamination, hydrolysis reactions, glucuronidation, sulfation and acetylation (see Goodman and Gilman's The Pharmacological Basis of Therapeutics (Tenth Edition), editor Hardman et al, publ. by McGraw-Hill, pages 12-18, (2001), which is hereby incorporated by reference).
  • halogen refers to fluorine, chlorine, bromine, and iodine substituents for the purposes of this invention.
  • the alkyl may be fully substituted, up to perhalo.
  • fused bicyclo ring refers to a substituent which is a two ring structure which share two carbon atoms.
  • the bonding between the fused bicyclo ring and the compound and/or atom to which it is attached can be through either of the two rings.
  • compositions comprising a therapeutically effective amount of one or more of the compounds of formula (I) or purified stereoisomers or stereoisomer mixtures of the invention, or their salts or prodrugs forms thereof, with a pharmaceutically acceptable ingredient.
  • Compounds for the purpose of forming pharmaceutical compositions for the inhibiting apoptosis, inducing apoptosis or treating cancer also includes the compounds of formula (I) wherein A is optionally hydrogen and the remaining variables are as defined above.
  • Brown et al. U.S. Patent 5,280,026 disclosed compounds where A is hydrogen. However, these compounds were utilized as inhibitors of the ⁇ ⁇ + ATPase enzyme useful in the treatment of gastric acid secretion.
  • compositions are prepared so that they may be administered orally, dermaily, parenterally, nasally, ophthalmically, otically, sublingually, rectally or vaginally.
  • Dermal administration includes topical application or transdermal administration.
  • Parenteral administration includes intravenous, intraarticular, intramuscular, and subcutaneous injections, as well as use of infusion techniques.
  • One or more compounds of the invention may be present in association with one or more non-toxic pharmaceutically acceptable ingredients and optionally, other active anti-proliferative agents, to form the pharmaceutical composition.
  • These compositions can be prepared by applying known techniques in the art such as those taught in Remington's Pharmaceutical Sciences (Fourteenth Edition), Managing Editor, John E. Hoover, Mack Publishing Co., (1970) or Pharmaceutical Dosage Form and Drug Delivery Systems (Sixth Edition), edited by Ansel et al., publ. by Williams & Wilkins, (1995), each of which is hereby incorporated by reference.
  • Commonly used pharmaceutical ingredients which can be used as appropriate to formulate the composition for its intended route of administration include: acidifying agents (examples include but are not limited to acetic acid, citric acid, fumaric acid, hydrochloric acid, nitric acid); alkalinizing agents (examples include but are not limited to ammonia solution, ammonium carbonate, diethanolamine, monoethanolamine, potassium hydroxide, sodium borate, sodium carbonate, sodium hydroxide, triethanolamine, trolamine); adsorbents (examples include but are not limited to powdered cellulose and activated charcoal); aerosol propellants (examples include but are not limited to carbon dioxide, CC1 2 F 2 , F 2 C1C- CC1F 2 and CC1F 3 ) air displacement agents (examples include but are not limited to nitrogen and argon); antifungal preservatives (examples include but are not limited to benzoic acid, butylparaben, ethylpara
  • clarifying agents include but are not limited to bentonite
  • emulsifying agents include but are not limited to acacia, cetomacrogol, cetyl alcohol, glyceryl monostearate, lecithin, sorbitan monooleate, polyethylene 50 stearate
  • encapsulating agents include but are not limited to gelatin and cellulose acetate phthalate
  • flavorants include but are not limited to anise oil, cinnamon oil, cocoa, menthol, orange oil, peppermint oil and vanillin
  • humectants include but are not limited to glycerin, propylene glycol and sorbitol
  • levigating agents include but are not limited
  • compositions can take the form of aerosols, capsules, creams, elixirs, emulsions, foams, gels, granules, inhalants, lotions, magmas, ointments, peroral solids, powders, sprays, syrups, suppositories, suspensions, tablets and tinctures.
  • the compositions of the invention can also have an additional apoptosis inducers as an active ingredient. Examples of known apoptosis inducers (see e.g.
  • Calbiochem's 2001 Signal Transduction Catalog, pages 702-704, the contents of which are incorporated by reference) which can be added to the described invention include but are not limited to A23187, N-Acetyl-L-cysteine, actinomycin D, tyrphostin A9, tyrphostin A25, AG 490, AG 1714, anandamide, anisomycin, aphidicolin, bafilomycin Al, berberine hemisulfate, betulinic acid, bleomycin sulfate, CAFdA, calphostin C, camptothecin, CAPE, chelerythrine chloride, 2-chloro-2'-deoxyadenosine, 2-chloro-2'-deoxyadenosine 5'-triphosphate, colcemid, cochicine, corticosterone, cycloheximide, cyclophosphamide monohydrate, cyclosporine A, daunorubicin hydroclor
  • Optional cancer treatment agents which can be added to the composition include but are not limited to compounds listed on the cancer chemotherapy drug regimens in the 11 th Edition of the Merck Index, (1996), which is hereby incorporated by reference, such as asparaginase, bleomycin, carboplatin, carmustine, chlorambucil, cisplatin, colaspase, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, doxorubicin (adriamycine), epirubicin, etoposide, 5-fiuorouracil, hexamethylmelamine, hydroxyurea, ifosfamide, irinotecan, leucovorin, lomustine, mechlorethamine, 6-mercaptopurine, mesna, methotrexate, mitomycin C, mitoxantrone, prednisolone, prednisone, procarbazin
  • cancer treatment agents suitable for use with the composition of the invention include but are not limited to those compounds acknowldeged to be used in the treatment of neoplastic diseases in Goodman and Gilman's The Pharmacological Basis of Therapeutics (Tenth Edition), editor Hardman et al., publ.
  • cancer treatment agents suitable for use with the composition of the invention include but are not limited to other anti-cancer agents such as epothilone.
  • the daily oral dosage regimen will preferably be from 0.01 to 200 mg/kg of total body weight.
  • the daily dosage for administration by injection including intravenous, intramuscular, subcutaneous and parenteral injections, and use of infusion techniques will preferably be from 0.01 to 200 mg/kg of total body weight.
  • the daily rectal dosage regimen will preferably be from 0.01 to 200 mg/kg of total body weight.
  • the daily vaginal dosage regimen will preferably be from 0.01 to 200 mg/kg of total body weight.
  • the daily topical dosage regimen will preferably be from 0.1 to 200 mg administered between one to four times daily.
  • the transdermal concentration will preferably be that required to maintain a daily dose of from 0.01 to 200 mg/kg.
  • the daily inhalation dosage regimen will preferably be from 0.01 to 100 mg/kg of total body weight.
  • the particular method of administration will depend on a variety of factors, all of which are considered routinely when administering therapeutics. It will also be understood, however, that the specific dose level for any given patient will depend upon a variety of factors, including, but not limited to the activity of the specific compound employed, the age of the patient, the body weight of the patient, the general health of the patient, the gender of the patient, the diet of the patient, time of administration, route of administration, rate of excretion, drug combinations, and the severity of the condition undergoing therapy.
  • the term 'concentrated under reduced pressure' refers to use of a Buchi rotary evaporator at approximately 15 mm of Hg.
  • Thin-layer chromatography was performed on Whatman ® pre-coated glass-backed silica gel 60A F-254 250 ⁇ m plates. Visualization of plates was effected by one or more of the following techniques: (a) ultraviolet illumination, (b) exposure to iodine vapor, (c) immersion of the plate in a 10% solution of phosphomolybdic acid in ethanol followed by heating, and/or (d) immersion of the plate in a cerium sulfate solution followed by heating. Column chromatography (flash chromatography) was performed using 230-400 mesh EM Science ® silica gel
  • Melting points (mp) were determined using a Thomas-Hoover melting point apparatus or a Mettler FP66 automated melting point apparatus and are uncorrected.
  • Proton (1H) nuclear magnetic resonance (NMR) spectra were measured with a General Electric GN-Omega 300 (300 MHz) spectrometer with either Me Si ( ⁇ 0.00) or residual protonated solvent (CHC1 3 ⁇ 7.26; MeOH ⁇ 3.30; DMSO ⁇ 2.49) as standard.
  • Carbon ( 13 C) ⁇ MR spectra were measured with a General Electric GN-Omega 300 (75 MHz) spectrometer with solvent (CDC1 3 ⁇ 77.0; d 3 -MeOD; ⁇ 49.0; d 6 -DMSO ⁇ 39.5) as standard.
  • HPLC - electrospray mass spectra were obtained using a Hewlett-Packard 1100 HPLC equipped with a quaternary pump, a variable wavelength detector set at 254 nm, a YMC pro C-18 column (2 x 23 mm, 120 A), and a Finnigan LCQ ion trap mass spectrometer with electrospray ionization. Spectra were scanned from 120-1200 amu using a variable ion time according to the number of ions in the source. The eluents were A: 2% acetonitrile in water with 0.02% TFA and B: 2% water in acetonirile with 0.018% TFA. Gradient elution from 10% B to 95% over 3.5 minutes at a flowrate of 1.0 mL/min was used with an initial hold of 0.5 minutes and a final hold at 95% B of 0.5 minutes. Total ran time was 6.5 minutes.
  • Step 1 2,4-dichlorothiophenol[3,2-d]pyrimidine.
  • a solution of dry DMF (8 mL) in POCl 3 (400 mL) was stirred at rt for 20 min. under Ar before it was added to thieno[3,2-d]pyrimidine-2,4-diol (100.0 g, 595 mmol).
  • the suspension was heated to a gentle reflux. After 5 h, the resultant dark yellow solution was cooled to 70 °C and slowly poured into vigorously stirred cold (0 °C) water (4000 mL) at a rate that kept the internal temperature below 20 °C. A solid precipitated immediately, after 10 min, the solution was filtered.
  • Step 3 Methyl 4-[( ⁇ 2-[(2-thienylmethyl)ammo]thieno[3,2-d]pyrimidin-4-yl ⁇ amino) methyljbenzoate.
  • Apoptosis (programmed cell death) is an essential process in the development and maintenance of homeostasis in an organism (1).
  • the growth fraction of a tumor is governed by the rate of cellular division as well as the rate of cell death: if the rate of division exceeds that of cell death, then net tumor expansion occurs.
  • net growth rates of tumors do not generally correlate directly with the rate, of cell division within the tumor, as assessed by the abundance of mitotic figures.
  • aberrant apoptotic rate plays an important role in tumor growth and expansion (2, 3).
  • Proteases are attractive cancer drug targets since they are known to regulate apoptotic signal transduction (8, 9).
  • work on apoptosis initiated by specific inhibitors of the proteasome complex has been reported in the literature, where lactacystin and other proteasome inhibitors are shown to cause apoptosis in a number of cell lines (10, 11).
  • prolylpeptidase As an intracellular protease involved in the repression of apoptosis and, as such, prolylpeptidase is thought to be an anti- apoptotic factor (12, 13).
  • Prolylpeptidase is a serine protease that is irreversibly inactivated by diispropyl-fluorophosphate (DFP) through covalent modification of Serl54 (12) and unpublished data. It is the only known human serine protease that is fully active without additional post-translational removal of inhibitory peptide. In addition, the enzyme is localized to novel non-lysosomal cytosolic vesicles (14).
  • prolylpeptidase as well as prolylpeptidase purified from natural sources are active as dimeric proteins (106 kDa), based on size exclusion chromatography, although the gene encodes a putative enzyme with a predicted mass of 58 kDa (15).
  • prolylpeptidase has been identified in a number of solid tumor cell lines of different histological types including those from colon (HCT116 and DLD1), prostate (PC3), and breast (MDA-MB-435).
  • expression data for prolylpeptidase mRNA shows a very limited distribution across adult human tissues, with highest levels observed in the testis, and moderate levels in prostate, skeletal muscle and brain.
  • Increased expression of prolylpeptidase mRNA in human tumor specimens and the published biological data on the enzyme suggest that prolylpeptidase plays an important role in tumor cell growth or survival. In summary, these data suggest that selective inhibition of prolylpeptidase activity in tumor cells could lead to increased apoptotic rates and growth inhibition.
  • Test compounds were diluted serially 1:5 in 5% DMSO/95% water and 5 ⁇ L was added to give 100 ⁇ L as a final volume to a well containing prolylpeptidase enzyme in buffer. Drug had a final concentration ranging from 10 ⁇ M to 0.12 ⁇ M.
  • the Ala-Pro- AFC dipeptide substrate (AFC is 7-amino-4-trifluoro-methylcoumarin) in MTEN buffer was used at a final concentration of 200 ⁇ L and the reaction was initiated with 10 nM final concentration of recombinant prolylpeptidase. The reaction was allowed to proceed for 20 min at room temperature and quenched with 20 ⁇ L of 1 M Glycine-HCl pH 2.5.
  • Ala-Pro-AFC is a dipeptide substrate with a conjugated AFC fluorophore at the C-terminus. Hydrolysis of the dipeptide substrate releases free AFC which is excited at 400 nm and emission of 505 nm in a spectrofluorometer.
  • Assay buffer is 50 mM MTEN Buffer pH 4.5 (50 n M MES, 25 mM Tris, 25 mM ethanolamine, 100 mM NaCl).
  • Enzyme storage buffer was 50 mM Tris pH 7.0, 50% glycerol and was stored at -80 °C. It was diluted in assay buffer just prior to initiation of the assay.
  • the induction of apoptosis by prolylpeptidase inhibitors was measured in whole cells using the multiparameter apoptosis assay (MPA).
  • MPA multiparameter apoptosis assay
  • the assay uses the ArrayScan II (Cellomics Inc.
  • test compounds were dissolved in 100% DMSO and diluted serially 1:2 in
  • DMEM fetal calf serum
  • DMSO concentration 0.25% 10% fetal calf serum
  • the final drag concentrations ranged from 25 ⁇ M to 0.39 ⁇ M.
  • Cells were exposed to compound for either one or 24 hours depending on the experiment.
  • the MPA assay was run according to the manufactures' protocol.
  • Example 15 was tested in the above apoptosis assay and found to induce apoptosis below a concentration of 25 ⁇ M.

Abstract

Les composés de l'invention sont des dérivés de thiénopyrimidine représentés par la formule (I) dans laquelle X est OR3 ou NR3R4; et q, R1, R2, R3, et R4 sont comme spécifiés dans le descriptif. Ces composés conviennent bien comme inhibiteurs de la prolylpeptidase, inducteurs d'apoptose et agents anti-cancéreux.
PCT/US2002/041168 2001-12-21 2002-12-20 Composes derives de thienopyrimidine utilises comme inhibiteurs de la prolylpeptidase, inducteurs d'apoptose et agents de traitement anticancereux WO2003055890A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002364211A AU2002364211A1 (en) 2001-12-21 2002-12-20 Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34304801P 2001-12-21 2001-12-21
US60/343,048 2001-12-21

Publications (1)

Publication Number Publication Date
WO2003055890A1 true WO2003055890A1 (fr) 2003-07-10

Family

ID=23344458

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/041168 WO2003055890A1 (fr) 2001-12-21 2002-12-20 Composes derives de thienopyrimidine utilises comme inhibiteurs de la prolylpeptidase, inducteurs d'apoptose et agents de traitement anticancereux

Country Status (2)

Country Link
AU (1) AU2002364211A1 (fr)
WO (1) WO2003055890A1 (fr)

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006111549A1 (fr) * 2005-04-21 2006-10-26 Boehringer Ingelheim International Gmbh Dihydrothienopyrimidines destines au traitement de maladies inflammatoires
JP2008506714A (ja) * 2004-07-16 2008-03-06 サネシス ファーマシューティカルズ， インコーポレイテッド オーロラキナーゼインヒビターとして有用なチエノピリミジン
US20110092499A1 (en) * 2007-11-15 2011-04-21 Ym Biosciences Australia Pty Ltd N-containing heterocyclic compounds
CN103242341A (zh) * 2013-04-19 2013-08-14 中国科学院广州生物医药与健康研究院 噻吩并2，4取代嘧啶类化合物及其药物组合物与应用
US8604039B2 (en) 2006-04-19 2013-12-10 Boehringer Ingelheim International Gmbh Dihydrothienopyrimidines for the treatment of inflammatory diseases
US8637519B2 (en) 2007-10-19 2014-01-28 Boehringer Ingelheim International Gmbh Heterocycle-substituted piperazino-dihydrothienopyrimidines
US8754073B2 (en) 2007-10-19 2014-06-17 Boehringer Ingelheim International Gmbh Substituted piperazino-dihydrothienopyrimidines
WO2015014815A1 (fr) * 2013-07-30 2015-02-05 Janssen R&D Ireland Dérivés de thiéno[3,2-d]pyrimidines destinés au traitement d'infections virales
US9090626B2 (en) 2007-10-19 2015-07-28 Boehringer Ingelheim International Gmbh Piperazino-dihydrothienopyrimidine derivatives
US9150586B2 (en) 2011-08-24 2015-10-06 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
US9802954B2 (en) 2011-08-24 2017-10-31 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
WO2018028721A1 (fr) * 2016-08-09 2018-02-15 厦门大学 Composé thiénopyrimidine, son procédé de préparation, composition pharmaceutique et applications associées
WO2018134685A3 (fr) * 2017-01-17 2018-11-15 Liverpool School Of Tropical Medicine Composés
CN109293519A (zh) * 2017-07-25 2019-02-01 北京斯利安药业有限公司 一种枸橼酸他莫昔芬晶型a的制备方法
CN109575045A (zh) * 2017-09-28 2019-04-05 南京红云生物科技有限公司 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用
US10253003B2 (en) 2012-11-16 2019-04-09 Janssen Sciences Ireland Uc Heterocyclic substituted 2-amino quinazoline derivatives for the treatment of viral infections
US10259793B2 (en) 2013-02-21 2019-04-16 Janssen Sciences Ireland Uc 2-aminopyrimidine derivatives for the treatment of viral infections
US10259814B2 (en) 2012-10-10 2019-04-16 Janssen Sciences Ireland Uc Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
US10266543B2 (en) 2013-03-29 2019-04-23 Janssen Sciences Ireland Uc Macrocyclic deaza-purinones for the treatment of viral infections
US10272085B2 (en) 2011-04-08 2019-04-30 Janssen Sciences Ireland Uc Pyrimidine derivatives for the treatment of viral infections
US10280180B2 (en) 2012-07-13 2019-05-07 Janssen Sciences Ireland Uc Macrocyclic purines for the treatment of viral infections
US10280167B2 (en) 2011-11-09 2019-05-07 Janssen Sciences Ireland Uc Purine derivatives for the treatment of viral infections
US10377738B2 (en) 2013-05-24 2019-08-13 Janssen Sciences Ireland Unlimited Company Pyridone derivatives for the treatment of viral infections and further diseases
US10385054B2 (en) 2013-06-27 2019-08-20 Janssen Sciences Ireland Unlimited Company Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
JP2020534308A (ja) * 2017-09-20 2020-11-26 レオ ファーマ アクティーゼルスカブ 置換ジヒドロチエノピリミジンおよびホスホジエステラーゼ阻害剤としてのその使用
US10968184B2 (en) 2016-09-29 2021-04-06 Janssen Sciences Ireland Unlimited Company Pyrimidine prodrugs for the treatment of viral infections and further diseases
US11053256B2 (en) 2016-07-01 2021-07-06 Janssen Sciences Ireland Unlimited Company Dihydropyranopyrimidines for the treatment of viral infections
CN113767100A (zh) * 2019-03-01 2021-12-07 锐新医药公司 双环杂芳基化合物及其用途
CN114105887A (zh) * 2021-09-16 2022-03-01 沈阳药科大学 一种氨基嘧啶衍生物及其制备方法和用途
WO2022058896A1 (fr) * 2020-09-15 2022-03-24 Cadila Healthcare Limited Inhibiteurs de la protéine tyrosine phosphatase de faible poids moléculaire (lmptp) utiles pour la prise en charge des troubles métaboliques
US11597704B2 (en) 2018-03-01 2023-03-07 Janssen Sciences Ireland Unlimited Company 2,4-diaminoquinazoline derivatives and medical uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1057612A (en) * 1964-01-15 1967-02-01 Thomae Gmbh Dr K Thieno-pyrimidines
EP0404356A1 (fr) * 1989-05-30 1990-12-27 Smithkline Beecham Intercredit B.V. Dérivés de thiénopyrimidine substitués, leur préparation, compositions pharmaceutiques et application médicale
WO1993017021A1 (fr) * 1992-02-19 1993-09-02 Pfizer, Inc. Composes heterocycliques ameliorant l'activite antitumorale
WO1999024440A1 (fr) * 1997-11-11 1999-05-20 Pfizer Products Inc. Derives de thienopyrimidine et thienopyridine utiles comme agents anticancereux
US5948911A (en) * 1998-11-20 1999-09-07 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to thienopyrimidine derivatives

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1057612A (en) * 1964-01-15 1967-02-01 Thomae Gmbh Dr K Thieno-pyrimidines
EP0404356A1 (fr) * 1989-05-30 1990-12-27 Smithkline Beecham Intercredit B.V. Dérivés de thiénopyrimidine substitués, leur préparation, compositions pharmaceutiques et application médicale
WO1993017021A1 (fr) * 1992-02-19 1993-09-02 Pfizer, Inc. Composes heterocycliques ameliorant l'activite antitumorale
WO1999024440A1 (fr) * 1997-11-11 1999-05-20 Pfizer Products Inc. Derives de thienopyrimidine et thienopyridine utiles comme agents anticancereux
US5948911A (en) * 1998-11-20 1999-09-07 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to thienopyrimidine derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; MODNIKOVA, G. A. ET AL: "Amine derivatives of pyrrolo[3,2-d]pyrimidines", XP002240292, retrieved from STN Database accession no. 109:242 *
KHIMIKO-FARMATSEVTICHESKII ZHURNAL (1988), 22(2), 185-91 *

Cited By (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008506714A (ja) * 2004-07-16 2008-03-06 サネシス ファーマシューティカルズ， インコーポレイテッド オーロラキナーゼインヒビターとして有用なチエノピリミジン
US8354531B2 (en) 2005-04-21 2013-01-15 Boehringer Ingelheim International Gmbh Compounds for the treatment of inflammatory diseases
US7723341B2 (en) 2005-04-21 2010-05-25 Boehringer Ingelheim International Gmbh Compounds for the treatment of inflammatory diseases
WO2006111549A1 (fr) * 2005-04-21 2006-10-26 Boehringer Ingelheim International Gmbh Dihydrothienopyrimidines destines au traitement de maladies inflammatoires
AU2006237354B2 (en) * 2005-04-21 2012-03-01 Boehringer Ingelheim International Gmbh Dihydrothienopyrimidines for the treatment of inflammatory diseases
US7511045B2 (en) 2006-04-19 2009-03-31 Boehringer Ingelheim International Gmbh Compounds for the treatment of inflammatory diseases
EP2060575A1 (fr) * 2006-04-19 2009-05-20 Boehringer Ingelheim International GmbH Dihydrothienopyrimidines et leur utilisation pour traiter des maladies inflammatoires
EA013108B1 (ru) * 2006-04-19 2010-02-26 Бёрингер Ингельхайм Интернациональ Гмбх Дигидротиенопиримидины для лечения воспалительных заболеваний
TWI380984B (zh) * 2006-04-19 2013-01-01 Boehringer Ingelheim Int 用於治療炎性疾病之新穎化合物
US8604039B2 (en) 2006-04-19 2013-12-10 Boehringer Ingelheim International Gmbh Dihydrothienopyrimidines for the treatment of inflammatory diseases
US8754073B2 (en) 2007-10-19 2014-06-17 Boehringer Ingelheim International Gmbh Substituted piperazino-dihydrothienopyrimidines
US9090626B2 (en) 2007-10-19 2015-07-28 Boehringer Ingelheim International Gmbh Piperazino-dihydrothienopyrimidine derivatives
US9115142B2 (en) 2007-10-19 2015-08-25 Boehringer Ingelheim International Gmbh Heterocycle-substituted piperazino-dihydrothienopyrimidines
US8637519B2 (en) 2007-10-19 2014-01-28 Boehringer Ingelheim International Gmbh Heterocycle-substituted piperazino-dihydrothienopyrimidines
US9499560B2 (en) 2007-11-15 2016-11-22 Ym Biosciences Australia Pty Ltd N-containing heterocyclic compounds
JP2016006113A (ja) * 2007-11-15 2016-01-14 ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド Ｎ含有複素環式化合物
US20110092499A1 (en) * 2007-11-15 2011-04-21 Ym Biosciences Australia Pty Ltd N-containing heterocyclic compounds
US8765755B2 (en) 2007-11-15 2014-07-01 Ym Biosciences Australia Pty Ltd. N-containing heterocyclic compounds
US8354408B2 (en) * 2007-11-15 2013-01-15 Ym Biosciences Australia Pty Ltd N-containing heterocyclic compounds
US10780089B2 (en) 2011-04-08 2020-09-22 Janssen Sciences Ireland Uc Pyrimidine derivatives for the treatment of viral infections
US10272085B2 (en) 2011-04-08 2019-04-30 Janssen Sciences Ireland Uc Pyrimidine derivatives for the treatment of viral infections
US11541050B2 (en) 2011-04-08 2023-01-03 Janssen Sciences Ireland Uc Pyrimidine derivatives for the treatment of viral infections
US10420767B2 (en) 2011-04-08 2019-09-24 Janssen Sciences Ireland Uc Pyrimidine derivatives for the treatment of viral infections
US9150586B2 (en) 2011-08-24 2015-10-06 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
US10745411B2 (en) 2011-08-24 2020-08-18 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
US9802954B2 (en) 2011-08-24 2017-10-31 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
US10280167B2 (en) 2011-11-09 2019-05-07 Janssen Sciences Ireland Uc Purine derivatives for the treatment of viral infections
US11104678B2 (en) 2011-11-09 2021-08-31 Janssen Sciences Ireland Unlimited Company Purine derivatives for the treatment of viral infections
US10280180B2 (en) 2012-07-13 2019-05-07 Janssen Sciences Ireland Uc Macrocyclic purines for the treatment of viral infections
US10822349B2 (en) 2012-07-13 2020-11-03 Janssen Sciences Ireland Unlimited Company Macrocyclic purines for the treatment of viral infections
US11220504B2 (en) 2012-10-10 2022-01-11 Janssen Sciences Ireland Unlimited Company Pyrrolo[3,2-d] pyrimidine derivatives for the treatment of viral infections and other diseases
US10259814B2 (en) 2012-10-10 2019-04-16 Janssen Sciences Ireland Uc Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
US10253003B2 (en) 2012-11-16 2019-04-09 Janssen Sciences Ireland Uc Heterocyclic substituted 2-amino quinazoline derivatives for the treatment of viral infections
US10723707B2 (en) 2012-11-16 2020-07-28 Janssen Sciences Ireland Unlimited Company Heterocyclic substituted 2-amino quinazoline derivatives for the treatment of viral infections
US10259793B2 (en) 2013-02-21 2019-04-16 Janssen Sciences Ireland Uc 2-aminopyrimidine derivatives for the treatment of viral infections
US10647684B2 (en) 2013-02-21 2020-05-12 Janssen Sciences Ireland Unlimited Company 2-aminopyrimidine derivatives for the treatment of viral infections
US10829494B2 (en) 2013-03-29 2020-11-10 Janssen Sciences Ireland Unlimited Company Macrocyclic deaza-purinones for the treatment of viral infections
US11702426B2 (en) 2013-03-29 2023-07-18 Janssen Sciences Ireland Unlimited Company Macrocyclic deaza-purinones for the treatment of viral infections
US10266543B2 (en) 2013-03-29 2019-04-23 Janssen Sciences Ireland Uc Macrocyclic deaza-purinones for the treatment of viral infections
CN103242341A (zh) * 2013-04-19 2013-08-14 中国科学院广州生物医药与健康研究院 噻吩并2，4取代嘧啶类化合物及其药物组合物与应用
US10377738B2 (en) 2013-05-24 2019-08-13 Janssen Sciences Ireland Unlimited Company Pyridone derivatives for the treatment of viral infections and further diseases
US10865193B2 (en) 2013-05-24 2020-12-15 Janssen Sciences Ireland Unlimited Company Pyridone derivatives for the treatment of viral infections and further diseases
US10385054B2 (en) 2013-06-27 2019-08-20 Janssen Sciences Ireland Unlimited Company Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
US10781216B2 (en) 2013-06-27 2020-09-22 Janssen Sciences Ireland Unlimited Company Pyrrolo [3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
US9556199B2 (en) 2013-07-30 2017-01-31 Janssen Sciences Ireland Uc Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
EP3404031A1 (fr) * 2013-07-30 2018-11-21 Janssen Sciences Ireland UC Dérivés de thiéno[3,2-d]pyrimidines utilisés dans le traitement d'infections virales
WO2015014815A1 (fr) * 2013-07-30 2015-02-05 Janssen R&D Ireland Dérivés de thiéno[3,2-d]pyrimidines destinés au traitement d'infections virales
CN105492446A (zh) * 2013-07-30 2016-04-13 爱尔兰詹森科学公司 用于治疗病毒性感染的噻吩并[3,2-d]嘧啶衍生物
KR20160035583A (ko) * 2013-07-30 2016-03-31 얀센 사이언시즈 아일랜드 유씨 바이러스 감염의 치료를 위한 티에노[3,2-d]피리미딘 유도체
EA036162B1 (ru) * 2013-07-30 2020-10-08 Янссен Сайенсиз Айрлэнд Юси Производные тиено[3,2-d]пиримидинов для лечения вирусных инфекций
KR102322425B1 (ko) 2013-07-30 2021-11-05 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염의 치료를 위한 티에노[3,2-d]피리미딘 유도체
US11053256B2 (en) 2016-07-01 2021-07-06 Janssen Sciences Ireland Unlimited Company Dihydropyranopyrimidines for the treatment of viral infections
WO2018028721A1 (fr) * 2016-08-09 2018-02-15 厦门大学 Composé thiénopyrimidine, son procédé de préparation, composition pharmaceutique et applications associées
US11078213B2 (en) 2016-08-09 2021-08-03 Hongyun Biotech Co., Ltd. Thienopyrimidine compound, preparation method thereof, pharmaceutical composition and application thereof
JP2019524790A (ja) * 2016-08-09 2019-09-05 ホンユン バイオテック カンパニー リミテッド チエノピリミジン系化合物、その製造方法、医薬組成物およびその応用
US20190211030A1 (en) * 2016-08-09 2019-07-11 Hongyun Biotech Co., Ltd. Thienopyrimidine compound, preparation method thereof, pharmaceutical composition and application thereof
AU2017311168B2 (en) * 2016-08-09 2021-03-04 Xiamen University Thienopyrimidine compound, preparation method therefor, pharmaceutical composition, and applications
KR102429355B1 (ko) * 2016-08-09 2022-08-04 홍윤 바이오테크 씨오., 엘티디. 티에노피리미딘 화합물, 그의 제조 방법, 약학 조성물 및 용도
CN107698603B (zh) * 2016-08-09 2022-04-08 南京红云生物科技有限公司 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用
KR20200026782A (ko) * 2016-08-09 2020-03-11 홍윤 바이오테크 씨오., 엘티디. 티에노피리미딘 화합물, 그의 제조 방법, 약학 조성물 및 용도
CN107698603A (zh) * 2016-08-09 2018-02-16 厦门大学 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用
US10968184B2 (en) 2016-09-29 2021-04-06 Janssen Sciences Ireland Unlimited Company Pyrimidine prodrugs for the treatment of viral infections and further diseases
WO2018134685A3 (fr) * 2017-01-17 2018-11-15 Liverpool School Of Tropical Medicine Composés
US11518760B2 (en) 2017-01-17 2022-12-06 Liverpool School Of Tropical Medicine Anti-Wolbachia pyrido[2,3-d]pyrimidine compounds
CN109293519B (zh) * 2017-07-25 2021-09-28 北京斯利安药业有限公司 一种枸橼酸他莫昔芬晶型a的制备方法
CN109293519A (zh) * 2017-07-25 2019-02-01 北京斯利安药业有限公司 一种枸橼酸他莫昔芬晶型a的制备方法
JP2020534308A (ja) * 2017-09-20 2020-11-26 レオ ファーマ アクティーゼルスカブ 置換ジヒドロチエノピリミジンおよびホスホジエステラーゼ阻害剤としてのその使用
JP7216719B2 (ja) 2017-09-20 2023-02-01 ユニオン・セラピューティクス・アクティエセルスカブ 置換ジヒドロチエノピリミジンおよびホスホジエステラーゼ阻害剤としてのその使用
US11866445B2 (en) 2017-09-20 2024-01-09 UNION therapeutics A/S Substituted dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
TWI780077B (zh) * 2017-09-28 2022-10-11 大陸商南京紅云生物科技有限公司 噻吩並嘧啶類化合物、其製備方法、藥用組合物及其應用
CN109575045B (zh) * 2017-09-28 2021-02-12 南京红云生物科技有限公司 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用
CN109575045A (zh) * 2017-09-28 2019-04-05 南京红云生物科技有限公司 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用
US11597704B2 (en) 2018-03-01 2023-03-07 Janssen Sciences Ireland Unlimited Company 2,4-diaminoquinazoline derivatives and medical uses thereof
CN113767100A (zh) * 2019-03-01 2021-12-07 锐新医药公司 双环杂芳基化合物及其用途
WO2022058896A1 (fr) * 2020-09-15 2022-03-24 Cadila Healthcare Limited Inhibiteurs de la protéine tyrosine phosphatase de faible poids moléculaire (lmptp) utiles pour la prise en charge des troubles métaboliques
CN114105887A (zh) * 2021-09-16 2022-03-01 沈阳药科大学 一种氨基嘧啶衍生物及其制备方法和用途
CN114105887B (zh) * 2021-09-16 2023-12-01 沈阳药科大学 一种氨基嘧啶衍生物及其制备方法和用途

Also Published As

Publication number Publication date
AU2002364211A1 (en) 2003-07-15

Similar Documents

Publication Publication Date Title
WO2003055890A1 (fr) Composes derives de thienopyrimidine utilises comme inhibiteurs de la prolylpeptidase, inducteurs d'apoptose et agents de traitement anticancereux
EP2847180B1 (fr) Cycloalcénopyrazoles substitués en tant qu'inhibiteurs de bub1 pour le traitement du cancer
WO2003055489A1 (fr) Composes derives de 2,4-diamino-pyrimidine utilises comme inhibiteurs de la prolylpeptidase comme inducteurs de l'apoptose et comme agents de traitement du cancer
US9765058B2 (en) Substituted benzylpyrazoles
US9745285B2 (en) Heteroaryl substituted pyrazoles
WO2003055866A1 (fr) Composes derives de quinazoline et de quinoline servant d'inhibiteurs de prolylpeptidase, d'inducteurs d'apoptose et d'agents therapeutiques anticancereux
US10562864B2 (en) Chemical modulators of immune checkpoints and therapeutic use
KR20230173083A (ko) Cdk 억제제 및 이의 사용 방법
CA3137458A1 (fr) Inhibiteurs de fgfr et leurs procedes d'utilisation
CA2916097A1 (fr) Benzylpyrazoles substitues
EP1651652B1 (fr) Composes tetrahydrobenzothienopyrimidinamine a substitution utiles pour le traitement de troubles hyper-proliferatifs
CA2907594A1 (fr) Indazoles substitues par heteroaryle
AU2014240003B2 (en) Coumarin derivatives and methods of use in treating hyperproliferative diseases
CA2916103A1 (fr) Pyrazoles a substitution diaminoheteroaryle
EP2976334A1 (fr) Indazoles substitués par diaminohétéroaryle
AU2019296085A1 (en) Heterocyclic compound as TRK inhibitor
EA026655B1 (ru) 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
JP2008509971A (ja) Ｅｇ５キネシンのインヒビターとして使用するためのベンゾチエノピリジン
US10501466B2 (en) WDR5 inhibitors and modulators
ES2927529T3 (es) Compuesto heterocíclico condensado
CN108137556B (zh) 1,4-二羰基-哌啶基衍生物
KR20150056550A (ko) 키나제 억제제로서의 디히드로피롤리디노-피리미딘
US20080221063A1 (en) Heterocyclic Sulfonamide Derivatives As Inhibitors Of Factor Xa
EP2768831B1 (fr) Composé destiné au traitement de l'hépatite c
WO2019134082A1 (fr) Nouveaux dérivés de pyrimidine utilisés en tant qu'inhibiteurs de mth1

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP